- A Dependable December – The unemployment rate finished December 2024 at 4.1%, a 0.1% decrease from November 2024. Nonfarm payroll increased by 256,000 in December, primarily in the healthcare, government, social assistance, and retail trade sectors (source: U.S. Bureau of Labor Statistics).
- Still Dominant – All but one of the Magnificent Seven stocks beat the S&P 500 in 2024, which returned 23.31%. NVIDIA posted a 171.2% gain, followed by Meta Platforms at 65.42%, Tesla at 62.52%, Amazon at 44.39%, Apple at 30.07%, and Alphabet at 35.51%. Microsoft was the only stock to fall short of the S&P 500, with a 12.09% gain in 2024 (source: The Motley Fool).
- Flying High – Delta Air Lines announced its fourth quarter and full year 2024 financial results, citing $5 billion of pre-tax income, $8 billion of operating cash flow, and $3.4 billion of free cash flow. Delta is also forecasting a first-quarter revenue growth of 7% to 9% (source: Delta).
- Inching Insurance – Small businesses (those with less than 50 workers) have seen medical care benefits that require employee contributions increase from 2014 to 2024. Monthly payments for single coverage plans increased from $121.80 to $170.92, while family coverage plans increased from $519.78 to $751.45 between March 2014 and March 2024. As a result, medical insurance participation rates dropped from 38% in 2014 to 33% in 2024 (source: U.S. Bureau of Labor Statistics).
- Slumping Shots – Moderna, an authorized COVID-19 manufacturer, cut its 2025 sales forecast by $1 billion following weak demand for its COVID-19 and RSV vaccines. The company is in the process of getting FDA approval for a new influenza and COVID-19 combination vaccine (source: Reuters).
- Shooting for the Stars – Goldman Sachs plans to combine three groups in its global banking and markets unit under the new name of Capital Solutions Group. This announcement comes after Goldman Sachs revealed it looks to grow its influence in the private credit market (source: Yahoo Finance).
- Legal Trouble – Apple is fighting a $1.8 billion lawsuit against United Kingdom iPhone and iPad users. The lawsuit alleges that Apple abused its dominant position by charging app developers a 30% commission through the App Store (source: Reuters).
- Making Moves – Johnson & Johnson, a multinational healthcare company, announced the acquisition of Intra-Cellular Therapies, a neurological drugmaker, for $14.6 billion. Johnson & Johnson will buy each share of Intra-Cellular Therapies for $132, a 39% premium on the stock’s January 10, 2025, close price (source: Reuters).
- Warming Up – 2024 was the warmest year on record across the globe, with a global surface temperature 2.32°F above the 20th-century average. The ten warmest years since 1850 have all occurred in the past decade (source: Climate.gov).
- Weathering the Storms – 2024 was the fourth-costliest year on record for natural disasters at $182.7 billion, recording 27 events with at least $1 billion in damages each. 2017 still holds the top slot with $395.9 billion in estimated damages, followed by 2005 with $268.5 billion and 2022 with $183.6 billion (source: Climate.gov).
This newsletter is provided for informational purposes only and does not constitute investment advice or a recommendation regarding any specific product or security. Past performance is not indicative of future results. You cannot invest directly in an index. All references to tax or legal matters are provided for informational purposes only. You should consult your legal or tax professional regarding your specific situation. All investing is subject to risk, including possible loss of principal.
For current fund holdings, please click on the related fund links included above.
Originally published January 17, 2025
For more news, information, and strategy, visit the Leveraged & Inverse Channel.
An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. Click here to obtain a Fund’s prospectus and summary prospectus or call 866-476-7523. A Fund’s prospectus and summary prospectus should be read carefully before investing.
Leveraged and Inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk and who actively manage their investments.
Direxion Funds Risks — An investment in the Funds involves risk, including the possible loss of principal. The Funds are non-diversified and include risks associated with concentration risk which results from the Funds’ investments in a particular industry or sector and can increase volatility over time. Active and frequent trading associated with a regular rebalance of a fund can cause the price to fluctuate, therefore impacting its performance compared to other investment vehicles. For other risks including correlation, compounding, market volatility and risks specific to an industry or sector, please read the prospectus.
Direxion Shares ETF Risks — An investment in the ETFs involves risk, including the possible loss of principal. The ETFs are non-diversified and include risks associated with concentration that results from an ETF’s investments in a particular industry, sector or company, which can increase volatility. The leveraged and inverse ETF utilize derivatives, such as futures contracts and swaps which are subject to market risks that may cause their price to fluctuate over time. The leveraged and inverse ETFs do not attempt to, and should not be expected to, provide returns which are a multiple of the return of their respective index or underlying security for periods other than a single day. The leveraged and inverse ETFs may also subject to leverage, correlation, daily compounding, market volatility and risks specific to an industry, sector or company. The non-leveraged ETFs are subject to certain risks, including imperfect index correlation and market price variance, which may decrease performance. The non-leveraged ETFs may invest in a relatively small number of issuers and, as a result, be subject to greater risk of loss with respect to its portfolio securities. The non-leveraged ETFs may experience greater fluctuation in its net asset value as compared to other investments. The non-leveraged ETFs may be appropriate for investors with a long-term investment time horizon, who primarily seek capital growth, and who are able to tolerate periods of prolonged price declines. Please read each ETF’s prospectus for a more complete description of the investment risks. There is no guarantee that an ETF will achieve its investment objective.
Hong Kong Investors — This website and the investment products referenced herein (“Website”) are directed to persons who are “Professional Investors” within the meaning of the Hong Kong Securities and Futures Ordinance (Cap. 571) (“Ordinance”). This Website is not directed to the general public in Hong Kong. You agree that your use of this Website is subject to you reviewing and acknowledging the terms of this disclaimer and the website’s terms of use. Information herein is not intended for Professional Investors in any jurisdiction in which distribution or purchase is not authorized. This Website does not provide investment advice or recommendations, nor is it an offer or solicitation of any kind to buy or sell any investment products. Direxion Asia Limited (“DAL”) is licensed with and regulated by the Securities Futures Commission of Hong Kong (“SFC”) (CE Number: BAZ386) to provide services to Professional Investors. DAL does not maintain nor is it responsible for the contents of this Website, which has not been approved by the SFC. DAL is an affiliate of other companies within the Direxion Group companies which may manage the products and provide the services described herein, which are not directed to the general public in Hong Kong. Companies within the Direxion Group which do not carry out regulated activities in Hong Kong are not subject to the provisions of the Ordinance. ALPS Distributors, Inc. is the distributor for the Direxion Shares in the United States only.
Distributor: ALPS Distributors, Inc.
